Who Paid My Doc
Oncaspar
Drug Oncology
NDC 72694-954-01
General payments
$271,086
Research payments
$30,048,609
Through program year 2025, $271,086 in general payments and $30,048,609 in research payments were reported against Oncaspar (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $592 | 27 |
| 2025 | Research | $323,382 | 1 |
| 2024 | General | $13,604 | 174 |
| 2024 | Research | $304,169 | 13 |
| 2023 | General | $13,272 | 254 |
| 2023 | Research | $64,367 | 1 |
| 2022 | General | $114,138 | 334 |
| 2022 | Research | $8,296,648 | 2 |
| 2021 | General | $11,996 | 212 |
| 2021 | Research | $10,162,035 | 4 |
| 2020 | General | $117,484 | 185 |
| 2020 | Research | $10,898,008 | 5 |
Breakdown
The top 5 of 26 recipients; each share is of general payments naming this product in 2025.
The top 5 of 14 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 16 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
1,186 general · 26 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.